MS drug hailed as landmark treatment by medics

A drug described as a landmark in treating multiple sclerosis is being reviewed for use in Europe. Trials suggest that Ocrelizumab can slow damage to the brain in two forms of MS, which offers a lot of hope for the future.

Results published in the New England Journal of Medicine showed that 33% of patients taking the drug deteriorated over time compared with 39% of those taking a placebo.

The study of patients with progressive MS found that patients taking the drug also displayed less brain loss in scans and scored better on the time needed to walk 7.6m.